Composite euglena tablet candy and preparation process thereof

Abstract

The invention discloses a composite euglena tablet candy and a preparation process thereof. The composite euglena tablet candy comprises the following components: euglena powder, a mixed strain, a celery seed extract, a sour cherry extract, a mango extract and lalang grass rhizome. The euglena powder, the mixed strain, the celery seed extract, the sour cherry extract, the mango extract and the lalang grass rhizome are compounded, the euglena has a good relieving effect on hyperuricemia and gout, xanthine oxidase can be reduced, uric acid generation is reduced, and inflammatory response is reduced; the balance of intestinal microbial flora can be improved and adjusted through the mixed strains, the immunity of the body is enhanced, the digestion function is improved, meanwhile, the celery seed extract, the sour cherry extract, the mango extract, the lalang grass rhizome and other auxiliary materials can synergistically assist in improving the effects of resisting gout, resisting oxidation and the like, meanwhile, the edibility is improved, and the rich taste of the candy is increased.

Description

Technical Field

[0001] The invention belongs to the field of tablet candies, and in particular relates to a composite euglena tablet candy and a preparation process thereof. Background Art

[0002] Gout is a common and complex type of arthritis. Gout patients often experience sudden joint pain at night. Commonly affected joints are the big toe, hand joints, knees, elbows, etc.; severe pain, edema, redness, swelling and inflammation will occur in the affected joints, which restrict people's activities and affect their daily life; the essential cause of gout is the increase in uric acid levels in the body, which causes the deposition of urate in the joints and kidneys, thus causing gout; in addition, intestinal flora is a general term for microorganisms colonizing the gastrointestinal tract of healthy humans. Intestinal microorganisms have a certain flora barrier effect, which is a reliable guarantee for the body to be protected from foreign bacterial infection. Ensuring that a sufficient amount of active probiotics can reach the end of the intestine can change the intestinal colonization flora, affect the host's immune and neuroendocrine functions, and promote the health of the body; at the same time, it is necessary to improve the edibility of compressed candies and the diversity of health functions, and to improve the fusion of each component raw material in the preparation process so that the performance is evenly distributed and improved. Summary of the invention

[0003] In view of the shortcomings of the above-mentioned prior art, the problem solved by the present invention is to provide a composite euglena compressed candy with good anti-gout effect, good edibility, improved and regulated balance of intestinal microbial flora, enhanced immunity of the body, improved digestive function, uniform component distribution, and balanced preparation effect, and a preparation process thereof.

[0004] To solve the above problems, the technical solution adopted by the present invention is as follows:

[0005] A composite euglena tablet candy comprises the following components: euglena powder, mixed strains, celery seed extract, sour cherry extract, mango extract, and Imperata root; the weight proportions of the components are: 40 to 50 parts of euglena powder, 5 to 10 parts of mixed strains, 2 to 3 parts of celery seed extract, 1 to 3 parts of sour cherry extract, 2 to 3 parts of mango extract, and 1 to 2 parts of Imperata root.

[0006] Furthermore, the weight proportions of the components are: 40 parts of euglena powder, 5 parts of mixed strains, 2 parts of celery seed extract, 1 part of sour cherry extract, 2 parts of mango extract, and 1 part of Imperata root.

[0007] Furthermore, the weight proportions of the components are: 45 parts of euglena powder, 8 parts of mixed strains, 2 parts of celery seed extract, 2 parts of sour cherry extract, 3 parts of mango extract, and 1 part of Imperata root.

[0008] Furthermore, the weight proportions of the components are: 50 parts of euglena powder, 10 parts of mixed strains, 3 parts of celery seed extract, 3 parts of sour cherry extract, 3 parts of mango extract, and 2 parts of Imperata root.

[0009] Furthermore, the mixed bacteria species include inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800.

[0010] Furthermore, the weight ratio of the inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and Lactobacillus fermentum CF1800 is 2:1:1.

[0011] A preparation process of a composite euglena tablet candy, the steps are as follows:

[0012] S1. First, the components of Euglena powder, mixed strains, celery seed extract, sour cherry extract, mango extract and Imperata root are crushed and passed through a 30-mesh sieve for later use;

[0013] S2, then adding celery seed extract, sour cherry extract, mango extract and Imperata cylindrica root into a spray pot filled with water; controlling the water-to-material weight ratio to be 5:1; obtaining an aqueous solution;

[0014] S3, fully mixing the euglena powder and the mixed strains, then spreading a layer of the mixture of the euglena powder and the mixed strains, then spraying the aqueous solution in step S2 on the upper end of the first layer of the mixture of the euglena powder and the mixed strains, then spreading a second layer of the mixture of the euglena powder and the mixed strains, and then spraying the aqueous solution in step S2, and repeating this process until the aqueous solution, the mixture of the euglena powder and the mixed strains are used up; obtaining a layered mixture; shaking the spray pot before spraying the aqueous solution;

[0015] S4, drying the layered mixture in step S3;

[0016] S5, after drying, the mixture is sent to a mixer for thorough stirring and mixing to obtain a mixture; finally, the stirred and mixed mixture of each component is sent to a high-speed tablet press for tableting and subsequent packaging.

[0017] Beneficial effects of the present invention

[0018] 1. The present invention compounds euglena powder, mixed strains, celery seed extract, sour cherry extract, mango extract, and Imperata root, so that the euglena has a good alleviating effect on hyperuricemia combined with gout, and can reduce xanthine oxidase to reduce uric acid production and reduce inflammatory response; the mixed strains can improve and regulate the balance of intestinal microbial flora, enhance the body's immunity, and improve digestive function. At the same time, auxiliary materials such as celery seed extract, sour cherry extract, mango extract, and Imperata root can achieve synergistic assistance to improve anti-gout, antioxidant and other effects, while improving edibility and increasing the rich taste of candy.

[0019] 2. Since the amount of auxiliary materials used is small, the present invention has developed a new mixing method. The present invention distributes celery seed extract, sour cherry extract, mango extract, and Imperata root in water to form an aqueous solution, and the aqueous solution is evenly sprayed on the mixture of euglena powder and mixed strains for layer-by-layer distribution, which greatly improves the uniformity and efficiency of subsequent mixing and improves the functional uniformity of subsequent molded products. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is an analysis chart of the effects of the composite Euglena compressed tablet candy of the present invention on the ankle joint swelling index and gait score of gout rats.

[0021] Figure 2 This is an analysis chart of the results of the serum biochemical test of gout rats using the composite Euglena compressed tablet candy of the present invention.

[0022] Figure 3 These are HE staining photographs of the right ankle joints of rats in each group of the present invention.

[0023] Figure 4 This is a graph analyzing the results of the composite Euglena compressed tablet candy of the present invention on the pathological scoring of gout rats. DETAILED DESCRIPTION

[0024] The present invention will be further described in detail below in conjunction with the accompanying drawings.

[0025] Example 1

[0026] A composite euglena tablet candy comprises the following components: euglena powder, mixed bacteria, celery seed extract, sour cherry extract, mango extract, and Imperata root; the weight proportions of the components are: 40 parts of euglena powder, 5 parts of mixed bacteria, 2 parts of celery seed extract, 1 part of sour cherry extract, 2 parts of mango extract, and 1 part of Imperata root; the mixed bacteria are inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800; the weight proportion of the inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800 is 2:1:1.

[0027] Example 2

[0028] A composite euglena tablet candy comprises the following components: euglena powder, mixed bacteria, celery seed extract, sour cherry extract, mango extract, and Imperata root; the weight proportions of the components are: 45 parts of euglena powder, 8 parts of mixed bacteria, 2 parts of celery seed extract, 2 parts of sour cherry extract, 3 parts of mango extract, and 1 part of Imperata root; the mixed bacteria are inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800; the weight proportion of the inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800 is 2:1:1.

[0029] Example 3

[0030] A composite euglena tablet candy comprises the following components: euglena powder, mixed bacteria, celery seed extract, sour cherry extract, mango extract, and Imperata root; the weight proportions of the components are: 50 parts of euglena powder, 10 parts of mixed bacteria, 3 parts of celery seed extract, 3 parts of sour cherry extract, 3 parts of mango extract, and 2 parts of Imperata root; the mixed bacteria are inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800; the weight proportion of the inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550, and fermented Lactobacillus CF1800 is 2:1:1.

[0031] The preparation process of the present invention is as follows:

[0032] A preparation process of a composite euglena tablet candy, the steps are as follows:

[0033] S1. First, the components of Euglena powder, mixed strains, celery seed extract, sour cherry extract, mango extract and Imperata root are crushed and passed through a 30-mesh sieve for later use;

[0034] S2, then adding celery seed extract, sour cherry extract, mango extract and Imperata cylindrica root into a spray pot filled with water; controlling the water-to-material weight ratio to be 5:1; obtaining an aqueous solution;

[0035] S3, fully mixing the euglena powder and the mixed strains, then spreading a layer of the mixture of the euglena powder and the mixed strains, then spraying the aqueous solution in step S2 on the upper end of the first layer of the mixture of the euglena powder and the mixed strains, then spreading a second layer of the mixture of the euglena powder and the mixed strains, and then spraying the aqueous solution in step S2, and repeating this process until the aqueous solution, the mixture of the euglena powder and the mixed strains are used up; obtaining a layered mixture; shaking the spray pot before spraying the aqueous solution;

[0036] S4, drying the layered mixture in step S3;

[0037] S5, after drying, the mixture is sent to a mixer for thorough stirring and mixing to obtain a mixture; finally, the stirred and mixed mixture of each component is sent to a high-speed tablet press for tableting and subsequent packaging.

[0038] The composite euglena compressed candy prepared in Example 2 above was used as a test object.

[0039] 1. Experimental Materials

[0040] 1.1 Drugs and reagents

[0041] Allopurinol tablets, Hefei Jiulian Pharmaceutical Co., Ltd., batch number 20221006. Colchicine tablets, Yunnan Botanical Pharmaceutical Co., Ltd., batch number 20230621. Potassium oxonate, Shanghai McLean Biochemical Technology Co., Ltd., batch number C15784654. Sodium urate, Shanghai McLean Biochemical Technology Co., Ltd., batch number C16381356. Uric acid test kit (item number 70925) Shandong Boco Bio-Industry Co., Ltd., batch number 10330025Y. Rat xanthine oxidase (item number AF3600-A), TNF-α (item number AF3056-A), IL-1β (item number AF2923-A) and IL-6 (item number AF3066-A) ELISA kits, Hunan Aifang Biotechnology Co., Ltd., batch numbers 20240420, 20240416, 20240423, and 20240415, respectively. Tween-80, Beijing Solebow Technology Co., Ltd., batch number 1215E019. Paraformaldehyde fixative, Wuhan Saiweier Biotechnology Co., Ltd., batch number CR2206002.

[0042] 1.2 Experimental animals

[0043] 60 male SD rats, 180-220 g, were purchased from Hangzhou Medical College, animal qualification certificate number SCXK (Zhejiang) 2024-0002. This experiment has been reviewed by the Animal Ethics Committee of Nanjing University of Chinese Medicine, ethics number 202402A050.

[0044] 1.3 Experimental instruments

[0045] Synergy HT microplate reader, Bio-Tek, USA. BK-280 fully automatic biochemical analyzer, Shandong Bo Ke Biological Industry Co., Ltd. 85-2A dual digital display constant temperature magnetic stirrer, Changzhou Su Rui Instrument Co., Ltd. FA1004 electronic balance, Li Chen Technology Co., Ltd.

[0046] 2. Experimental Methods

[0047] 2.1 Preparation of modeling reagents

[0048] References Methods [1], weigh 3g potassium oxonate, add 97mL 0.9% saline, stir and mix at 70℃ to prepare a 3% potassium oxonate suspension, cool and set aside. Weigh 250mg sodium urate crystals, add 9mL saline and 1mL Tween 80, heat and stir to mix the solution thoroughly, and prepare a mass concentration of 25mg·mL -1 Sodium urate suspension was stored at 4°C for future use.

[0049] 2.2 Grouping and Dosing

[0050] Male SD rats were divided into a blank group, a model group, a positive drug group, and a low-, medium-, and high-dose group of the compound Euglena tablet candy, with 10 rats in each group. The blank group and the model group were gavaged with an equal volume of saline. The daily human dose of the compound Euglena tablet candy is 3.5 g, and the rat equivalent dose is 0.3 g·kg -1 As a low dose, the medium and high doses are 0.6 g kg -1 and 1.2 g kg -1 The positive group was first gavaged with allopurinol 0.1 g·kg for 4 consecutive days. -1 On the 5th day, colchicine 0.35×10 -3 g·kg -1 The other groups were gavaged with corresponding drugs once a day for 7 consecutive days. The blank group and the model group were gavaged with an equal volume of distilled water.

[0051] 2.3 Reproduction of the rat model of hyperuricemia combined with gout [1]

[0052] Except for the blank group, other rats were intraperitoneally injected with 3% potassium oxonate suspension 10 μL g -1 , 2 times / d, for 7 consecutive days. On the 5th day, the rats were anesthetized, and a No. 5 sterile syringe was inserted from the posterior side of the right ankle joint along the medial side of the Achilles tendon at a 30°-40° angle into the joint cavity, and 25 mg·mL -1 The mice were injected with 200 μl sodium urate suspension for 3 consecutive days. The blank group was injected with equal volume of saline intraperitoneally or combined with intra-articular injection at the corresponding time.

[0053] 2.3.Indicator detection:

[0054] 2.3.1 Joint swelling index and gait score [2]

[0055] Ankle joint swelling index: Before injection of sodium urate, 24h and 48h after injection, the circumference of the same part of the right ankle joint was measured by the wire-binding method. Ankle joint swelling index = [(after modeling / before modeling) right ankle joint circumference] × 100%.

[0056] Gait score: The rat joint swelling index and gait score were evaluated. Gait score: The gait and behavioral performance of the rats were observed before, 24h and 48h after the injection of sodium urate to determine the gait score. 0 points for normal walking with both feet; 1 point for mild lameness and the right lower limb can touch the ground but slightly bent; 2 points for moderate lameness and the right lower limb can touch the ground but immediately retracted; 3 points for severe lameness and the right lower limb cannot touch the ground.

[0057] 2.3.2 Serum biochemical test

[0058] On the evening of the sixth day of administration, the rats were fasted but not watered for 8 h. One hour after the last administration, blood was collected from the abdominal aorta under 3% isoflurane anesthesia and centrifuged (2000 r·min) after blood coagulation. -1 ) for 10 min, and serum was collected. Serum uric acid content was detected by biochemical method, and serum xanthine oxidase, TNF-α, IL-1β and IL-6 content were determined by Elisa method.

[0059] 2.3.3 Histopathological examination of rat ankle synovium

[0060] Rats were anesthetized with 3% isoflurane and blood was collected before being killed by cervical dislocation. The right ankle joint tissue was obtained, the tissue around the joint was removed and the joint cavity was retained. After fixation with 4% paraformaldehyde, the tissue was dehydrated with gradient concentrations of ethanol and embedded in paraffin. The tissue blocks were cut into 5 μm thick slices, stained with hematoxylin-eosin, dehydrated with ethanol, transparentized with xylene, and then covered with gum. The pathological changes of synovial tissue were observed under a light microscope and pathological scores were performed. The scoring criteria are as follows [3] .

[0061] (1) Synovial tissue swelling: none (0 points), mild (1 point), moderate (2 points), and severe (3 points);

[0062] (2) Inflammatory cell infiltration: none (0 points), mild (1 point), moderate (2 points), and severe (3 points);

[0063] (3) Hyperplasia of small blood vessels and fibroblasts: none (0 points), mild (1 point), moderate (2 points), and severe (3 points).

[0064] 2.4 Statistical methods

[0065] Graphpad Prism 8 was used for data analysis and graphing, and the results are presented as mean ± standard deviation. One-way analysis of variance was used to analyze the data between multiple groups, and P < 0.05 indicated that the difference between the two groups was statistically significant.

[0066] 3. Experimental results

[0067] 3.1 Joint swelling index and gait score results

[0068] Compared with the blank group, the swelling index of the right ankle joint in the model group increased significantly 24h and 48h after the injection of sodium urate (P<0.01), and reached a peak at 48h. The swelling index of the affected ankle joint was significantly reduced in the medium and high dose groups of the compound Euglena compressed tablet candy (P<0.05). In addition, the gait analysis at 24h and 48h showed that the normal group showed a normal gait, while the gait score of the model group was significantly higher than that of the blank group (P<0.01), and the rats showed a three-legged gait characteristic. Similar to the swelling index, the gait score was significantly reduced in the medium and high dose groups of the compound Euglena compressed tablet candy (P<0.05). The results are shown in Figure 1 shown.

[0069] 3.2 Serum biochemical test results

[0070] Compared with the blank group, the serum levels of uric acid, xanthine oxidase, IL-1β, IL-6 and TNF-α in the model group rats were significantly increased (P<0.01). Compared with the model group, the low, medium and high dose groups of the compound Euglena tablet candy could reduce the levels of uric acid and xanthine oxidase (P<0.05, 0.01), the medium and high dose groups could reduce the levels of IL-6 and TNF-α (P<0.05, 0.01), and the high dose group could reduce the level of IL-1β (P<0.05), indicating that the compound Euglena tablet candy could reduce the serum uric acid level of gout rats, improve the abnormal uric acid metabolism, and relieve the inflammatory response caused by hyperuricemia gout. The results are shown in Figure 2 shown.

[0071] 3.3 Histopathological results of rat ankle synovial membrane

[0072] In the blank group, the synovial tissue structure of the right ankle joint was clear, the synovial cells were arranged normally, the structure was complete and smooth, the joint cavity was visible, and there was basically no inflammatory cell infiltration and capillary hyperplasia. In the model group, obvious inflammatory cell infiltration of the synovial tissue was observed, and the synovial tissue proliferated and further filled the joint cavity. In the positive drug group, the synovial tissue was slightly swollen, the cells slightly proliferated, and a small amount of inflammatory cell infiltration and capillary hyperplasia were observed. In the low-dose and medium-dose groups of the composite naked algae compressed candy group, the synovial tissue hyperplasia was reduced, the joint cavity space increased, and the inflammatory cell infiltration and capillary hyperplasia were reduced. In the high-dose group of the composite naked algae compressed candy group, the synovial tissue structure was clearer, and the synovial cell hyperplasia and inflammatory cell infiltration were further significantly improved. The results are shown in Figure 3 .

[0073] In addition, pathological scores were performed based on the degree of synovial tissue swelling, inflammatory cell infiltration, and the degree of proliferation of small blood vessels and fibroblasts. The results showed that the pathological score of the synovial tissue of the ankle joint of rats in the model group was significantly higher than that in the normal group (P<0.01), and the score in the positive group was significantly reduced (P<0.01). The three dose groups of the composite euglena tablet candy also showed a decrease in pathological scores, and showed a good dose-effect relationship (P<0.05, 0.01). Figure 4 shown.

[0074] Results: The swelling degree, gait score, serum uric acid, xanthine oxidase, IL-1β, IL-6, TNF-α and pathological score of the model group rats were significantly increased (P<0.01). Euglena compound tablets can effectively reduce the swelling degree of ankle joints in model rats, improve gait behavior, reduce serum uric acid, xanthine oxidase, IL-1β, IL-6 and TNF-α content, and reduce the pathological score of ankle joints (P<0.05, 0.01). Conclusion: Euglena compound tablets have a good alleviating effect on hyperuricemia combined with gout, and its mechanism may be related to reducing xanthine oxidase and reducing uric acid production, as well as reducing inflammatory response.

[0075] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

[0076] References

[0077] [1] Li Jiachuan, Li Siying, Song Qin, et al. Exploring the mechanism of action of total flavonoids from rattan tea against gouty arthritis based on multi-level interaction network and in vivo experiments[J]. Chinese Journal of Traditional Chinese Medicine, 2022, 47(17): 4733-4743.

[0078] [2] Zhang Shuo, Wen Bo. Effects of Qingre Yangyin Chushi Pills on inflammatory factors and joint function in gout rats[J]. Shaanxi Journal of Traditional Chinese Medicine, 2023, 44(11): 1518-1522.

[0079] [3] Zhou Ziqian, Nurmanati Huanbek, Hamurati Hasmu, et al. Experimental study on the anti-inflammatory effect of Qiuju Pills on acute gouty arthritis in rats [J]. Pharmacology and Clinical Medicine of Traditional Chinese Medicine, 2023, 39(04): 24-28.

Claims

1. A composite euglena tablet candy, characterized in that: The invention comprises the following components: euglena powder, mixed bacteria, celery seed extract, sour cherry extract, mango extract and Imperata root; the weight proportions of the components are: 40 to 50 parts of euglena powder, 5 to 10 parts of mixed bacteria, 2 to 3 parts of celery seed extract, 1 to 3 parts of sour cherry extract, 2 to 3 parts of mango extract and 1 to 2 parts of Imperata root.

2. The composite euglena pressed candy according to claim 1, characterized in that: The weight proportions of the components are: 40 parts of euglena powder, 5 parts of mixed strains, 2 parts of celery seed extract, 1 part of sour cherry extract, 2 parts of mango extract, and 1 part of Imperata root.

3. The composite euglena pressed candy according to claim 1, characterized in that: The weight proportions of the components are: 45 parts of euglena powder, 8 parts of mixed strains, 2 parts of celery seed extract, 2 parts of sour cherry extract, 3 parts of mango extract, and 1 part of Imperata root.

4. The composite euglena pressed candy according to claim 1, characterized in that: The weight proportions of the components are: 50 parts of euglena powder, 10 parts of mixed strains, 3 parts of celery seed extract, 3 parts of sour cherry extract, 3 parts of mango extract, and 2 parts of Imperata root.

5. The composite euglena pressed candy according to claim 1, characterized in that: The mixed bacterial species include inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550 and fermented Lactobacillus CF1800.

6. The composite euglena pressed candy according to claim 5, characterized in that: The weight ratio of the inactivated Lactobacillus plantarum LP220, Lactobacillus plantarum 550 and Lactobacillus fermentum CF1800 is 2:1:

1.

7. A process for preparing the composite Euglena tablet candy according to claim 1, characterized in that: Here are the steps: S1. First, the components of Euglena powder, mixed strains, celery seed extract, sour cherry extract, mango extract and Imperata root are crushed and passed through a 30-mesh sieve for later use; S2, then adding celery seed extract, sour cherry extract, mango extract and Imperata cylindrica root into a spray pot filled with water; controlling the water-to-material weight ratio to be 5:1; obtaining an aqueous solution; S3, fully mixing the euglena powder and the mixed strains, then spreading a layer of the mixture of the euglena powder and the mixed strains, then spraying the aqueous solution in step S2 on the upper end of the first layer of the mixture of the euglena powder and the mixed strains, then spreading a second layer of the mixture of the euglena powder and the mixed strains, and then spraying the aqueous solution in step S2, and repeating this process until the aqueous solution, the mixture of the euglena powder and the mixed strains are used up; obtaining a layered mixture; shaking the spray pot before spraying the aqueous solution; S4, drying the layered mixture in step S3; S5, after drying, the mixture is sent to a mixer for thorough stirring and mixing to obtain a mixture; finally, the stirred and mixed mixture of each component is sent to a high-speed tablet press for tableting and subsequent packaging.

Images